It is a hallucinogenic drug, and is a controlled substance designed for use as an aesthetics. It also has now been touted for ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Also in the news, "renal denervation" shows promise as a treatment for high blood pressure; an estimated 17 million U.S. adults struggle with long-covid with no new treatments in sight; inequality ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...

Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray for serious depression – five psychiatrists who used the therapy on their patients have ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...